Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS

Nuvectis Pharma (NASDAQ:NVCT) posted its quarterly earnings results on Wednesday. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.05), FiscalAI reports.

Nuvectis Pharma Stock Performance

Shares of NASDAQ NVCT traded down $0.27 during trading hours on Wednesday, hitting $8.47. The company’s stock had a trading volume of 2,161 shares, compared to its average volume of 69,888. Nuvectis Pharma has a 12 month low of $5.55 and a 12 month high of $11.52. The stock has a market cap of $216.92 million, a price-to-earnings ratio of -6.18 and a beta of -0.29. The business has a 50-day simple moving average of $8.05 and a 200-day simple moving average of $6.91.

Institutional Investors Weigh In On Nuvectis Pharma

A number of large investors have recently made changes to their positions in the business. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Nuvectis Pharma during the second quarter valued at approximately $28,000. Oppenheimer & Co. Inc. boosted its holdings in Nuvectis Pharma by 6.5% in the fourth quarter. Oppenheimer & Co. Inc. now owns 73,566 shares of the company’s stock valued at $555,000 after acquiring an additional 4,500 shares in the last quarter. JPMorgan Chase & Co. increased its position in Nuvectis Pharma by 3,398.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after purchasing an additional 6,084 shares during the period. Bank of America Corp DE increased its position in Nuvectis Pharma by 417.2% during the 2nd quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after purchasing an additional 6,909 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Nuvectis Pharma in the 2nd quarter worth $53,000. 96.77% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on NVCT shares. HC Wainwright reiterated a “buy” rating on shares of Nuvectis Pharma in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuvectis Pharma in a research note on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.